牛牛AI助理已提取核心訊息
On January 12, 2024, FOXO Technologies Inc., a Delaware corporation, entered into a Master Software and Services Agreement with KR8 AI Inc., a Nevada corporation. The agreement grants FOXO Technologies a perpetual license to use KR8 AI's products for developing applications based on FOXO's epigenetic biomarker technology. The license is limited to the U.S., Canada, and Mexico, and includes an initial license and development fee of $2.5 million, a monthly maintenance fee of $50,000, and a 15% royalty on subscriber revenues. Additionally, FOXO Technologies issued 1,300,000 shares of common stock to KR8 AI on January 19, 2024, as part of the agreement. The shares were exempt from registration under the Securities Act of 1933, as amended, in reliance on an exemption provided by Rule 506(b) of Regulation D of the Securities Act.
On January 12, 2024, FOXO Technologies Inc., a Delaware corporation, entered into a Master Software and Services Agreement with KR8 AI Inc., a Nevada corporation. The agreement grants FOXO Technologies a perpetual license to use KR8 AI's products for developing applications based on FOXO's epigenetic biomarker technology. The license is limited to the U.S., Canada, and Mexico, and includes an initial license and development fee of $2.5 million, a monthly maintenance fee of $50,000, and a 15% royalty on subscriber revenues. Additionally, FOXO Technologies issued 1,300,000 shares of common stock to KR8 AI on January 19, 2024, as part of the agreement. The shares were exempt from registration under the Securities Act of 1933, as amended, in reliance on an exemption provided by Rule 506(b) of Regulation D of the Securities Act.
2024年1月12日，特拉華州的一家公司FOXO Technologies Inc. 與內華達州的一家公司KR8 AI Inc. 簽訂了主軟件和服務協議。該協議授予FOXO Technologies的永久許可，允許其使用KR8 AI的產品開發基於FOXO的表觀遺傳生物標誌物技術的應用程序。該許可證僅限於美國、加拿大和墨西哥，包括250萬美元的初始許可和開發費、50,000美元的每月維護費以及訂戶收入的15％的特許權使用費。此外，作爲協議的一部分，FOXO Technologies於2024年1月19日向KR8 AI發行了13萬股普通股。根據經修訂的1933年《證券法》，根據《證券法》D條第506（b）條規定的豁免，這些股票免於註冊。
2024年1月12日，特拉華州的一家公司FOXO Technologies Inc. 與內華達州的一家公司KR8 AI Inc. 簽訂了主軟件和服務協議。該協議授予FOXO Technologies的永久許可，允許其使用KR8 AI的產品開發基於FOXO的表觀遺傳生物標誌物技術的應用程序。該許可證僅限於美國、加拿大和墨西哥，包括250萬美元的初始許可和開發費、50,000美元的每月維護費以及訂戶收入的15％的特許權使用費。此外，作爲協議的一部分，FOXO Technologies於2024年1月19日向KR8 AI發行了13萬股普通股。根據經修訂的1933年《證券法》，根據《證券法》D條第506（b）條規定的豁免，這些股票免於註冊。
有用
沒用